Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)

Shun Yamamoto, Ken Kato, Hiroyuki Daiko, Takashi Kojima, Hiroki Hara, Tetsuya Abe, Yasuhiro Tsubosa, Kengo Nagashima, Kazunori Aoki, Yukihiro Mizoguchi, Shigehisa Kitano, Shinichi Yachida, Satoshi Shiba, Yuko Kitagawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

One of the standard treatments of resectable esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemotherapy followed by surgery. Nivolumab showed efficacy for metastatic ESCC. However, the safety and efficacy of neoadjuvant nivolumab with chemotherapy for ESCC is unknown. Therefore, we will conduct FRONTiER to evaluate the safety and efficacy of nivolumab adding to neoadjuvant chemotherapy. FRONTiER comprises four experimental cohorts: (A) including nivolumab plus 5-FU+CDDP (cisplatin and 5-fluorouracil [CF]); (B) including one prior administration of nivolumab and the cohort A regimen; (C) including nivolumab plus docetaxel+ CF; (D) including one prior administration of nivolumab and the cohort C regimen; an expanded cohort. The primary end point is the incidence of dose-limiting toxicities from the initial dose to the 30th postoperative day. Clinical Trial Identifier: NCT0391444.

Original languageEnglish
Pages (from-to)1351-1357
Number of pages7
JournalFuture Oncology
Volume16
Issue number19
DOIs
Publication statusPublished - 2020 Jul

Keywords

  • 5-fluorouracil
  • cisplatin
  • docetaxel
  • esophageal squamous cell carcinoma
  • immune checkpoint inhibitor
  • neoadjuvant chemotherapy
  • nivolumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)'. Together they form a unique fingerprint.

  • Cite this

    Yamamoto, S., Kato, K., Daiko, H., Kojima, T., Hara, H., Abe, T., Tsubosa, Y., Nagashima, K., Aoki, K., Mizoguchi, Y., Kitano, S., Yachida, S., Shiba, S., & Kitagawa, Y. (2020). Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future Oncology, 16(19), 1351-1357. https://doi.org/10.2217/fon-2020-0189